AGENDIA
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.agendia.com
Clinical Trials
8
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)โข Click on a phase to view related trials
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- Conditions
- Breast Cancer
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Agendia
- Target Recruit Count
- 30000
- Registration Number
- NCT03053193
- Locations
- ๐บ๐ธ
CHS Grandview, Birmingham, Alabama, United States
๐บ๐ธProvidence Alaska Medical Center, Anchorage, Alaska, United States
๐บ๐ธArizona Oncology Associates, PC, Phoenix, Arizona, United States
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
- Conditions
- Breast Cancer
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2018-06-27
- Lead Sponsor
- Agendia
- Target Recruit Count
- 481
- Registration Number
- NCT02670577
- Locations
- ๐บ๐ธ
Desert Regional Medical Center, Palm Springs, California, United States
๐บ๐ธUniversity of Miami, Miami, Florida, United States
๐บ๐ธSt. Joseph's Women's Hospital, Tampa, Florida, United States
The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients
- Conditions
- Chinese
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2019-07-02
- Lead Sponsor
- Agendia
- Target Recruit Count
- 64
- Registration Number
- NCT02669745
- Locations
- ๐บ๐ธ
Columbia University Medical Center, New York, New York, United States
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score
- Conditions
- Hormone Receptor Positive Malignant Neoplasm of Breast
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Agendia
- Target Recruit Count
- 820
- Registration Number
- NCT01617954
- Locations
- ๐บ๐ธ
Maricopa Integrated Health System, Phoenix, Arizona, United States
๐บ๐ธProvidence Saint Joseph Medical Center, Burbank, California, United States
๐บ๐ธComprehensive Cancer Center, Palm Springs, California, United States
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
- Conditions
- Breast Cancer
- Interventions
- Drug: TAC chemotherapyDrug: TCH chemotherapyDrug: TC chemotherapyDrug: T + trastuzumab followed by CEF + trastuzumabDrug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapyDrug: Dose dense AC followed by T + trastuzumabDrug: Dose dense AC followed by T + trastuzumab + pertuzumab
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Agendia
- Target Recruit Count
- 226
- Registration Number
- NCT01501487
- Locations
- ๐บ๐ธ
University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
๐บ๐ธMorton Plant Mease Health Care, Clearwater, Florida, United States
๐บ๐ธUniversity of Miami, Miami, Florida, United States
- Prev
- 1
- 2
- Next
News
Agendia's BluePrint Test Shows Promise in Identifying Chemotherapy-Responsive Breast Cancer Subtypes
New FLEX Study data reveals BluePrint molecular subtyping assay can identify Basal-type tumors among MammaPrint High Risk HR+ HER2- breast cancers that respond better to chemotherapy.